Danvatirsen sodium by AstraZeneca for Oral Cavity (Mouth) Cancer: Likelihood of Approval

Retrieved on: 2023-10-27 22:51:41

Tags for this article:

Click the tags to see associated articles and topics

Danvatirsen sodium by AstraZeneca for Oral Cavity (Mouth) Cancer: Likelihood of Approval. View article details on HISWAI: https://www.pharmaceutical-technology.com/uncategorized/danvatirsen-sodium-astrazeneca-oral-cavity-mouth-cancer-likelihood-of-approval-2/

Excerpt

Danvatirsen sodium is under clinical development by AstraZeneca and currently in Phase II for Oral Cavity (Mouth) Cancer.

Article found on: www.pharmaceutical-technology.com

View Original Article